Destiny Pharma appoints NOMAD and Joint Broker

/in

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Appointment of NOMAD and Joint Broker

Brighton, United Kingdom – 9 May 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces the appointment of finnCap Ltd as Nominated Adviser to the Company and WG Partners as joint broker to the Company, with immediate effect. finnCap remains joint broker to the Company. 

For further information, please contact:

Destiny Pharma plc 
Neil Clark, CEO 
Shaun Claydon, CFO 
pressoffice@destinypharma.com 
+44 (0)1273 704 440

FTI Consulting 
Simon Conway / Victoria Foster Mitchell 
destinypharma@fticonsulting.com 
+44 (0) 20 3727 1000

finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500

WG Partners (Joint Broker) 
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com